Danaher vs. Medtronic: Which Stock Has More Upside Now?
Two healthcare giants are staging recoveries. Here's which one gives traders the better risk-reward setup right now.
Healthcare is back on traders' radars, and two names keep coming up in the same breath: Danaher and Medtronic. Both are coming off rough patches, both are trying to prove they deserve a rerating — but only one is likely to get you paid faster.
Danaher built its reputation on precision science tools and diagnostics. Post-pandemic, the COVID testing tailwind turned into a brutal headwind, and the stock paid the price. The bull case now rests on a bioprocessing rebound — the idea that biopharma customers who destocked aggressively are finally ready to reorder. If that cycle turns, Danaher's margins could snap back hard and fast.
Read more Real and RE/MAX Complete Merger, Trade as REAX on Nasdaq →
Medtronic is a different kind of recovery play. It's a legacy medical device company that has been restructuring, spinning off units, and trying to reignite organic growth after years of underperformance. The upside is real but slower — more of a show-me story that demands patience from investors who've already waited a long time.
For active traders, Danaher's leverage to the bioprocessing upcycle is a cleaner, more catalyst-driven setup. Medtronic's turnaround has more moving parts and a longer runway before the thesis is proven. That doesn't make Medtronic a bad hold — it makes it a different kind of bet, better suited to value-oriented, longer-duration portfolios than momentum-driven accounts.
Both companies carry real risks: Danaher is still working through inventory normalization, and Medtronic faces competitive pressure across its device segments. Know your time horizon before you size up either position. Continue reading at Yahoo Finance.
